PriceTargets.com logo

Aytu BioPharma - AYTU Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.16 As of 04/1/2025 05:00 PM ET
▼ -0.04 (-3.33%)

This chart shows the closing price for AYTU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMar$1.20Closing price on 03/31/25:
Get New Aytu BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AYTU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AYTU

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Aytu BioPharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.16.

This chart shows the closing price for AYTU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/254/26$0.81$1.53$2.25$2.98$3.70Closing price on 03/31/25: $1.20High$0.0000Average$0.0000Low$10.00M




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Aytu BioPharma. This rating has held steady since August 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/7/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/9/2023Maxim GroupInitiated CoverageBuy$5.00
2/22/2023Cantor FitzgeraldReiterated RatingOverweight
7/21/2022HC WainwrightLower TargetBuy$11.00 ➝ $6.00
5/17/2022Cantor FitzgeraldLower Target$11.00 ➝ $5.00
4/28/2022HC WainwrightLower TargetBuy$24.00 ➝ $11.00
6/18/2021LADENBURG THALM/SH SHReiterated RatingBuy$14.50
3/29/2021Cantor FitzgeraldInitiated CoverageOverweight$11.00
8/6/2020HC WainwrightReiterated RatingBuy$3.00
5/29/2020HC WainwrightInitiated CoverageBuy$3.00
(Data available from 4/1/2020 forward)

News Sentiment Rating

1.92 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2025

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Aytu BioPharma logo
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.
Read More

Today's Range

Now: $1.16
Low: $1.16
High: $1.21

50 Day Range

MA: $1.38
Low: $1.16
High: $1.72

52 Week Range

Now: $1.16
Low: $1.15
High: $3.45

Volume

18,558 shs

Average Volume

27,361 shs

Market Capitalization

$7.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Aytu BioPharma?

The following sell-side analysts have issued reports on Aytu BioPharma in the last year:
View the latest analyst ratings for AYTU.

What is the current price target for Aytu BioPharma?

0 Wall Street analysts have set twelve-month price targets for Aytu BioPharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aytu BioPharma in the next year.
View the latest price targets for AYTU.

What is the current consensus analyst rating for Aytu BioPharma?

Aytu BioPharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AYTU.

What other companies compete with Aytu BioPharma?

Other companies that are similar to Aytu BioPharma include Rallybio, Generation Bio, Clene, Cognition Therapeutics and Tenax Therapeutics. Learn More about companies similar to Aytu BioPharma.

How do I contact Aytu BioPharma's investor relations team?

Aytu BioPharma's physical mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company's listed phone number is (720) 437-6580 and its investor relations email address is james@haydenir.com. The official website for Aytu BioPharma is aytubio.com. Learn More about contacing Aytu BioPharma investor relations.





Receive Aytu BioPharma News & Ratings Daily
Sign up to receive the latest news and ratings for Aytu BioPharma and its competitors with PriceTargets.com’s free daily newsletter.